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Backgrounds & Aims: Glycoprotein 2(GP2) and CUB zona pellucida-like domain 
1(CUZD1) belong to protein families involved in gut innate immunity processes and 
have recently been identified as specific targets of anti-pancreatic 
autoantibodies(PAbs) in Crohn’s disease(CD). We aimed to determine the prognostic 
potential of novel target specific PAbs regarding long-term disease course of an adult 
CD patient cohort. Methods: Sera of 458 consecutive well-characterized IBD patients 
from a single referral IBD center were tested by enzyme-linked immunosorbent 
assay(ELISA) with isoform 4 of recombinant GP2(anti-MZGP2 and anti-GP2 
IgA/IgG)  and indirect immunofluorescence test(IIFT) system with GP2 and CUZD1 
expressing transfected HEK 293 cells(anti-rPAg2 and rPAg1 IgA/IgG)  . Clinical data 
were available on evolvement of complicated disease or surgical interventions as well 
as disease activity and medical treatment during the prospective follow-up (median, 
108 months).Results: 12.4% and 20.8% of CD patients were positive for IgA/IgG 
type of anti-GP2 and anti-CUZD1, respectively, with a significant difference 
compared to UC (p<0.01). Antibody status was stable over time. Agreement among 
three different anti-GP2 assays was good. Positivity for PAbs, mainly IgA subtypes, 
predicted a faster progression towards complicated disease course. In Kaplan-Meier 
analysis, time to surgery or development of perianal disease was associated withanti-
GP2 IgA(pLogRank<0.01) or anti-CUZD1 IgA(pLogRank<0.001) positivity, 
respectively. Anti-CUZD1 IgAremained an independent predictor in multivariate 
Cox-regression model (HR:3.43, 95%CI: 1.68–7.02, p<0.001).Conclusions: The 
present study has shown that specific PAbs (especially IgA subtype) are predicting 
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Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the 
gastrointestinal tract. Both Crohn’s disease (CD) and ulcerative colitis (UC) are 
heterogeneous in their presentation and disease course. Serological antibodies have 
been reported to assist in the diagnosis, differential diagnosis, and prediction of either 
disease course or response to therapy in IBD1. There is accumulating evidence from 
cross-sectional, longitudinal studies and meta-analyses that support the value of 
serological markers in identifying patients with complicated disease phenotype and 
increased risk of surgery in patients with CD. Anti-Saccharomyces cerevisiae 
antibody (ASCA) has been identified as the most accurate single marker in CD, yet.It 
is questionable if other markers can identify a specific subset of CD patients2. 
Enhanced formation of autoantibodies against acinar cells of the exocrine 
pancreas in patients with CD and celiac disease was reported3.Presence of pancreatic 
autoantibodies (PAb) was identified first by indirect immunofluorescence technique 
(IIFT)4  and human and primate pancreas substrate has been used as the primary 
diagnostic test for PAbso far. PAbare present up to 40% of the patients with CD and 
can be used to differentiate CD from UC2.Furthermore some studies, including the 
one with the largest patient cohort, have suggested that presence of PAbsis associated 
with specific disease phenotypes and their detection may be of clinical significance5, 6. 
More recently, the target antigens of PAbshave been identified: the pancreatic 
major glycoprotein GP2 of the zymogen granule membrane and CUZD1 protein 
(CUB and zona pellucida-like domains 1)7, 8. In the study of Komorowski et al.,they 
verified that the formerly reported reticulogranular pattern intissue sections of human 
pancreas by IIFTis strictly correlated with the presence of anti-CUZD1, whereas 












of GP2 and CUZD1 revealed that they belong to protein families involved in innate 
and adaptive immunity10, 11. Presumably GP2 and CUZD1 may be involved in 
maintaining the balance between tolerance to commensal bacteria and immune 
response against pathogens12. 
Identification of the autoantigens has facilitated the development of 
newdiagnostic tools for evaluation of PAbs, such as enzyme-linked immunosorbent 
assay (ELISA) with isoform 4 of recombinant GP213 or advanced CUZD1 and GP2 
expressing cell-based IIFT14.Experience with these newly available techniques for 
PAb detectionis scarce, especially on the clinical importance of PAbsin CD. 
Recombinant GP2-based ELISA systems were used primarily in these studies. In 
contrast, information about anti-CUZD1 is very limited9Presence of anti-GP2 was 
associated to stricturing behavior with perianal disease in some15-17but not all 
studies18. However, studies were limited by cross-sectional design. Longitudinal 
follow-up studies are needed to unravel the clinical importance of these antibodies in 
the prediction of CD prognosis. For this, studies should also investigate long-term 
stability of PAbs 
 The primary aimof the present study was to determine the predictive potential 
of the different PAbs with regards to the development of disease specific 
complications or need for surgery in a large prospective referral CD cohort. The 
secondary aims wereto investigate (1) the long-term stability of the PAbs response (2) 
association of PAbs formation to the clinical, serologic and genetic characteristics of 
CDand lastly (3) to define the agreement between the new diagnostic tools for the 












MATERIAL AND METHODS 
Patient population 
We performed a cohort study among adult CD and UC patients in one tertiary IBD 
referral center of Hungary (Department of Gastroenterology, Institute of Internal 
Medicine, University of Debrecen). In all, 458 well-characterized, unrelated, 
consecutive IBD patients with a complete clinical follow-up (CD: 271 [male/female: 
120/140, median age at presentation: 25 years (inter quartile range [IQR], 19-33)] and 
UC: 187 [male/female: 86/101, median age at presentation, 33 years  (IQR, 23-
43)])seen at our outpatient clinic were included between January 1, 2005 and June 1, 
2010.  
The clinical characteristics of the patients at diagnosis are presented in Table 
1. Diagnosis of IBD was based on the Lennard–Jones criteria19.The disease phenotype 
(age at onset, duration, location, and behaviour) was determined according to the 
Montreal Classification20.Blood samples and detailed clinical phenotypes were 
captured at inclusion. Clinical datawere determined by thorough review of patients’ 
medical records, which had been collected in a uniform format. Medical records that 
documented the disease phenotype, presence of extraintestinal manifestations (EIM) 
(for example, arthritis: peripheral and axial; ocular manifestations: conjunctivitis, 
uveitis, iridocyclitis; skin lesions: erythemanodosum, pyoderma gangrenosum; and 
hepatic manifestations: primary sclerosing cholangitis [PSC]), frequency of flare-ups 
(frequent flare-up: >1 clinical relapse/year)21,medication use (e.g., steroid, 
immunosuppressive and/or biological use at any time), need for surgery (resection in 
CD and colectomy in UC), the presence of familial IBD, smoking habits, and perianal 
involvement were retrospectively analyzed for the period prior to the prospective 
follow-up.At enrolment, clinical disease activity was calculatedaccording to the 












study we followed the ECCO (European Crohn’s and Colitis Organisation) 
guidelines24 and defined HBI ≤4 as a state of remission and ≥5 as a state of active 
disease. In case of UC ≤ 3 was defined as a state of remission and >4 as a state of 
active disease. Endoscopic activity was determined according to the Simple 
Endoscopic Score for Crohn’s Disease (SES-CD) in CD25 and the endoscopic 
component of the Mayo score in UC26. SES-CD defines endoscopic activity ≥3 points 
and inactive disease ≤2 in CD, meanwhile in UC state of active disease was defined 
as invasive partial Mayo score ≥1. 
  
Phenotypical characterization of CD patients during prospective follow-up 
CD patients were enrolled into a prospective follow-up study, where the treating IBD 
physicians registered laboratory data, endoscopic and imaging findings, disease 
activity, medical treatment, date and type of complications and surgery during regular 
and extraordinary outpatient follow-up visits and inpatient stays. In Hungary, a 
follow-up visit is usually scheduled for every 6 months at a specialized 
gastroenterology center (the actual interval varies between 3–6 months). The 
treatment algorithms, both the medical and surgical, are harmonized and followed the 
actual ECCO guidelines24, 27-30. A need for surgery and timing of the resection is a 
consistent multidisciplinary decision with the collaboration of the gastroenterologist, 
radiologist and surgeon. Collected data were transferred and stored in a database for 
analysis. In October 1, 2013, all patients’ charts and database were reviewed and 
updated for the data points mentioned above. Follow-up for a particular patient was 
terminated if there was no further record available. Median follow-up from diagnosis 
was 108 months (IQR, 65-178). In CD, complicated disease behavior was defined as 












distinguished from internal penetrating disease and evaluated separately. Need for 
surgery was defined as CD-related abdominal surgery (resection). Figure 
1summarizes flow chart of the patients with CD in the cohort study.  
The control group consisted of 100 age- and gender-matched healthy blood 
donors (male/female: 46/54, median age at presentation, 30 years  (IQR,21-40)]. The 
control subjects did not have any gastrointestinal and/or liver disease and were 
selected from consecutive blood donors in Debrecen. 
 
Serological Analysis 
Blood samples were obtained at enrollment from each patient and were frozen at -
80℃ until testing.All the serological assays were performed in a blinded fashion 
without prior knowledge of the patients’ diagnosis or other clinical information. 
 
Detection of antibodies to GP2 by enzyme-linked immunosorbent assays(ELISA) 
Glycoprotein 2 autoantibodies were detected in sera of patients and controls using two 
different ELISAs employing recombinant human GP2 isoform 4 as solid-phase 
antigen(anti-MZGP2 IgA and IgG QUANTA Lite® ELISA [Inova Diagnostics, San 
Diego, CA, Research Use Only] and anti-GP2 IgA and IgG ELISA [GA Generic 
Assays, Dahlewitz/Berlin, Germany]) according to the manufacturer instructions. 
Briefly, 100 µl of pre-diluted sera (1:100) was added to separate wells of MZGP2 or 
GP2 antigen-coated polystyrene microwells and incubated for 30 min. and 60 min., 












peroxidase-conjugated goat anti-human IgA antibody or anti-human IgG antibody 
was added to each well and developed with ready-to-use hydrogen peroxide/ 
tetramethylbenzidine chromogenic substrate. The reaction was terminated with 
sulphuric acid and optical density of the samples was read at wavelength of 450/620 
nm. Results expressed in arbitrary units (AU/ml), were calculated in reference to a kit 
provided calibrator. Serum samples showing ≥25 AU/mlfor anti-MZGP2 and 
≥20AU/ml for anti-GP2, respectively were interpreted as positive. 
 
Detection of antibodies to GP2 and CUZD1 by indirect immunofluorescence tests 
(IIFT) 
Anti-GP2 and anti-CUZD1 IgA and IgG were detected in sera of patients and controls 
usingcell-based IIFT(Morbus-Crohn Mosaic 1, 
EuroimmunMedizinischeLabordiagnostikaAG,Lübeck, Germany).Biochips coated 
with transfected HEK293 cells, expressing GP2 and CUZD1 separately, are applied as 
substrates and were co-incubated with pre-diluted sera (exactly 1:10, 1:100 and 
1:1000)for 30 min. at room temperature.Unbounded sample was then washed away 
and fluorescein-labeled goat anti-human IgA or IgG antibodies were used to visualize 
bound antibodies of the patients’ sera.Evaluation was performed under using a 
Eurostar Plus microscope with Bluelight LED 
(EuroimmunMedizinischeLabordiagnostika AG).Supporting Figure 1shows 
immunofluorescence staining patterns on HEK293 transfected with either CUZD1 or 
GP2.According to findings of Komorowski et al.9reaction with transfected HEK293 












on frozen sections of the human pancreas, whereas GP2-HEK reaction does the 
droplet pattern (type 2). 
 
Antibody Assays for anti-Saccharomyces cerevisiae antibodies (ASCA) 
ASCA antibody evaluation in CD patients was performed by ELISA (QUANTA 
LiteTM, Inova Diagnostics, San Diego, CA) according to the manufacturers’ 
instructions. The results are presented as arbitrary units, and values above the cut-off 
of 25 units were considered as positive. The results were documented in absolute 
values and in frequency of positivity. 
 
Detection of NOD2/CARD15 SNP8, 12, 13 mutations  
NOD2/CARD15 SNP8, SNP12, and SNP13 genotypes were performed previously31  
in CD patients (n=235), but not in UC patients. NOD2/CARD15 variants were 
detected by denaturing high-performance liquid chromatography (dHPLC, Wave 
DNA Fragment Analysis System, Transgenomic Limited, UK). Sequence variation, 
observed in the dHPLC profile, was sequenced on both strands to confirm the 
alteration. Sequencing reactions were performed with the ABI BigDye Terminator 
Cycle Sequencing Kit v1.1 (Applied Biosystems, Foster City, CA) and samples were 
sequenced on an ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, 















The regional and national committee [DEOEC RKEB/IKEB 3515-2011, 
3880/2012/EKU (59/PI/2012)] for research ethics approved the study protocol. Each 
patient was informed of the nature of the study and signed an informed consent form. 
Statistical analysis 
Variables were tested for normality using Shapiro Wilk’s W test. Continuous 
variables were summarized as means [standard deviation (SD)] or as medians 
[interquartile range (IQR)] according to their homogeneity. To evaluate differences 
between IBD and healthy control group, as well as within subgroups of patients with 
IBD, the following statistical methods were used. Categorical variables were 
compared with the Fisher’s exact test or χ2-test with Yates correction, linear-by-linear 
association, as appropriate. Continuous variables were compared with Student’s t test, 
one-way analysis of variance (ANOVA), or Mann-Whitney’s U test or Kruskal-
Wallis H test with Post-hoc analysis (Dunn’s multiple comparison test). Kaplan-Meier 
survival curves were plotted for analyzing the association between categorical clinical 
variables or serological antibodies and complicated disease outcomes during follow-
up with LogRank test or Cox-regression analysis in the time-dependent models. 
Associations are given as odds ratio (OR) and hazard ratio (HR) with a 95% 
confidence intervals (CI). A 2-sided probability value <0.05 was considered to be 
statistically significant. For statistical analysis, GraphPadPrism 6 (San Diego, CA) 















Frequency of anti-pancreatic antibodies in IBD  
The frequency of the different antibodies in IBD and controls is summarized in Table 
2. Significantly more, 10.2%, 12.2%, 10.2% and 20.8% of the CD patients were 
positive for anti-GP2 IgA/IgG, anti-MZGP2 IgA/IgG, anti-rPAg2 IgA/IgG and also 
for anti-CUZD1 (≈anti-rPAg1) IgA/IgG antibodies compared to both UC and healthy 
controls (p<0.01 for all), respectively. In addition, significant differences were found 
for both IgA and IgG subtypes. In contrast, the positivity rate was not different in UC 
and controls. 
Anti-GP2 and anti-MZGP2 antibody titers were higher in CD compared to 
UC. The difference of the median titers for all antibodies, except anti-MZGP2 IgA, 
between CD and UC was statistically significant (Mann-Whitney, anti-GP2 IgA 
p<0.001, anti-GP2 IgG p<0.001, anti-MZGP2 IgA p=0.12, anti-MZGP2 IgG 
p<0.001). 
 
Correlation ofanti-pancreatic antibodies formation and overall disease 
durationin Crohn’s disease 
 
Stability of anti-pancreatic antibodies in Crohn’s disease 
No association was detected between antibody status and clinical or endoscopic 
disease activity (actual HBI or SES-CD)at the time of sample procurement (data not 
shown).In addition, to evaluate the stability of PAbsstatus (positive or negative for a 
respective antibody), we analyzed samples from same patients over various arbitrary 












themajority of CD patients (n=192)and re-tested for all the different PAb. Median 
time between sample procurements was 30.3months [IQR, 15.3-48.7].Interestingly, 
the status of different PAbswas very stable over time regarding both IgA and IgG 
subtypes with only ≤ 5% of cases changing their PAb status over time. Stability data 
of PAbsare summarized in Supporting Information Table 2.Development of disease 
complications or surgical procedure did also not affect the antibody status of any of 
thePAbs (data not shown). 
 
Predictive potential of anti-pancreatic antibodiesfor disease outcomes in Crohn’s 
disease 
We analyzed the association of the different PAb markers with poor disease 
outcomes (development of internal penetrating and/or stricturing disease, perianal 
perforating disease and need for first and subsequent surgical resection) in time-
dependent univariate models. 
None of the PAb markers were able to predict the development of internal 
penetrating and/orstricturingcomplications in patients with inflammatory disease 
behavior (B1) (n=211). 
Among patients without previous perianal complication (any behavior) 
(n=216) , those who were positive for anti-CUZD1 IgA/IgG more likely progressed to 
developperianal complications (pLogRank=0.008). The association was stronger for 
the IgA antibody subtype (pLogRank<0.001) and a quantitative association was also 
found with IgA antibody titers (pLogRank<0.001) (Figure 3).The sensitivity analysis 
performed in patients withB1-ponly behaviour(n=169)after excluding patients with an 












perianal complications (pLogRank<0.001 for the anti-CUZD1 IgA).  
In the surgery-naïve patient group (n=234), progression to first resective 
surgery was faster in patients positive for anti-GP2 IgA antibody (pLogRank=0.002) 
(Figure 2). At the same time, in postoperative setting, the presence of anti-GP2 IgA 
antibody was not able to predict a subsequent resective surgery in patients with prior 
surgery (n=109). 
To further evaluate the predictive potential of the PAb markers, we used a 
Cox-proportional Hazard regression model adjusted to gender and clinical variables 
with a p value of < 0.1 in univariate time dependent models (Kaplan-Meier and Log-
rank analysis). Anti-CUZD1 IgA and anti-GP2 IgA were analyzed separately. Anti-
CUZD1 IgA was identified as an independent predictor for the development of 
perianal disease both in the primary model(Table 4)and also in the model in the same 
sensitivity analysis (data not shown).In contrast,  the association between anti-GP2 
andneed for resective surgery was lost in the multivariate model (Table 4). 
 
Association betweenanti-pancreatic antibody positivity and clinical, serologic 
and genetic characteristics of Crohn’s disease 
Anti-MZGP2 IgA/IgG antibodies were more prevalent in patients with 
pediatric disease onset (A1: 28.6%, A2:11.3%, A3:5.7%, p=0.012)and anti-rPAg2 
IgA/IgG antibodies (L1/3 vs. L2, 13.2% vs. 4.5%, p=0.032) were more frequent in 
patients with ileal involvement.Penetrating disease behavior at last follow-upwas 
associated withanti-GP2 IgA/IgG (17.9% vs. 7.3%, p=0.026),anti-MZGP2 IgA/IgG 












In addition, anti-GP2 IgA/IgG (14.5% vs. 6.6%, p=0.036) was associated with need 
for resective surgery at maximum follow-up. Of the extraintestinal manifestations, 
anti-rPAg2 IgA/IgG positivity was associated withPSC (37.5% vs. 9.4%, p=0.038). In 
contrast, PAb directed against CUZD1 (≈anti-rPAg1) was associated withcolonic 
involvement (L2/L3 vs. L1, 23.7% vs. 10.5%, p=0.041 for IgA/IgG subtype), perianal  
diseaseat maximum follow-up (P1 vs. P0, 32.6% vs. 15.0%, p=0.001 for IgA/IgG 
subtype) and cutaneous manifestations(23.5% vs. 10.4%, p=0.044 for IgA 
subtype).Table 3 presents the associations between antibody reactivities to different 
PAbs and diseases characteristics in patients with CD at diagnosis and maximum 
follow-up according to Ig subtypes.There was an association between the presence of 
IgA type PAbs and ASCA antibodies. The different PAb IgA antibodies were 
significantly more frequent in ASCA IgA positives compared to negatives (anti-GP2 
IgA: 6.7% vs. 0.0%, anti-MZGP2 IgA: 14.6% vs. 1.7%, anti-rPAg1: 17.5% vs. 4.9% 
and anti-rPAg2: 11.7% vs. 2.4%, p< 0.01 for all). However, PAb IgG positivity did 
not differ significantly according to presence or absence of ASCA IgG (Table 3). The 
prevalence of different PAbs was also not associated with the presence or absence of 
major NOD2/CARD15mutations (data not shown).  
 
Interassay study for anti-GP2 antibodies 
Altogether, the agreement among the three different assays ranged from 94.0% to 
95.6% for anti-GP2 IgG and from 91.6% to 96.4% for anti-GP2 IgA. The κ 
coefficients suggested good concordance between the different assays. The exact 














In the present study, we investigated the clinical importance of different target 
specific PAbs in the prediction of complicated diseases behavior and surgery in adult 
CD patients. To our knowledge, this is the first prospective study on the new PAbs. In 
addition, we proved the long-term stability of PAb status over time and confirmed 
good agreement among newly availablediagnostic tools for evaluation of anti-GP2 
antibodies. 
Significantly more CD patients were positive for different PAbs compared to 
both UC patients and healthy controls. The formation of autoantibodies against GP2 
and CUZD1 glycoproteins may reflect an immune response against an overwhelmed 
microbial challenge to the intestinal barrier. Anti-GP2 antibody titers were higher in 
CD compared to UC as well. The magnitude of antibody responses (titers) may 
correlate with the extent of bacterial translocation (BT), which is more pronounced in 
CD compared to UC. One possible explanation is that in UC the inflammation is 
confined to the mucosa whereas in CD it is transmural. Another explanation might be 
that the disturbance of mucosal immunity is different between the two diseases. It is 
further supported by the findings that the presence of GP2 was confirmed at the 
intestinal site of inflammation in patients with CD32. 
In previous clinical studies, presence of anti-GP2 antibodies was associated 
with distinct clinical phenotype of CD such as early disease onset, ileal involvement 
and stricturingdisease behavior but results differedamong studies. However, in the 
single study identifying anti-CUZD1 antibody as a distinct PAb type the association 
with clinical phenotype or disease course has not been assessed in CD9.Interestingly, 
clinical associations were different for anti-GP2 and anti-CUZD1 antibodies in the 












target proteins of these antibodies belonging to distinct innate immunity protein 
family. Prevalence of anti-GP2 antibodies was higher in our patients with pediatric 
onset in concordance with findings of some previous studies14, 15. Regarding disease 
location, we were also able to confirm thatpresence of anti-GP2 antibodies was 
associated with extensive disease with ileal involvement14-16. Of note, some 
reportsfailed to identify an association between anti-GP2 antibodies and disease 
location33or this was limited to only upper gastrointestinal tract involvement18.Anti-
CUZD1 antibodies were more frequent in patients with colonic 
involvement.Penetrating disease was associated with anti-GP2 positivity in the 
present CD cohort. In the study of Bogdanos et al.15 anti-GP2 IgG were significantly 
more prevalent in patients with stricturing behavior and perianal disease,but less 
prevalent in those with penetrating behavior, while other studies did not find 
significant associationbetween anti-GP2 antibodies and complicated disease 
behavior14, 18. Thus far, no studies have evaluated associations between target specific 
PAbs and extraintestinal manifestations. We found that PSC was associated with the 
presence of anti-GP2 while ocular manifestations were associated with anti-CUZD1 
antibodies. Of note, despite these differences between the clinical phenotypes the 
concordance among the three assays was good. Each test recognized also an 
additional patient population that was missed by the other(s), suggesting partly non-
overlapping epitopes.  
Our findings support that PAbs may contribute to better stratification of CD 
patients. Prevalence is relatively low and so the clinical utility of PAbs in the 
diagnosis and prediction disease course in CDmay be more modest compared to 
ASCA which remains the most accurate single marker in CD so far2.However, anti-












specificity of double positive patients with CD is 100%14. Of note, the prevalence rate 
of anti-GP2 IgA/IgG in our CD patients was even lower than those ones reported 
previously (10.2-12.4% vs. 21.0-45.0%)34. Variation in the prevalence of serologic 
markers among studies and in different ethnic populations is however well 
documented2. Moreovermethodological differences can also contribute to these 
differences. It is interesting to note that different isoforms of GP2 are synthesized in 
the pancreas35.A larger and a shorter isoform of GP2 were identified and termed them 
alpha (GP2a) and beta (GP2b), respectively36. Previous prevalence data of anti-GP2 
IgA and IgG, except one14, wereobtained mainly by assays manufactured by GA 
Generic Assays employing the larger isoform for GP2-specific autoantibody detection 
initially13.In contrast, both ELISAs used in our study employed recombinant human 
GP2 isoform 4 as solid-phase antigencorresponding to the shorter isoform (GP2b) due 
to better discrimination of patients with CD from those with UC35. 
For the long-term predictive potential of serologic markersit is necessary to 
assess the stability of antibody statusover time. In terms of anti-GP2 antibody 
stability, only limited and conflicting data are available17. In the present study long-
term stability of different PAbs wasassessed extensively. PAb status wasnot 
associated with actual disease activity and positivity rates were stable over time in 
IBD patients. This is in contrast to anti-GP2 antibody levels detected in patients with 
celiac disease where they were significantly reduced under a gluten-free diet3. 
Until now, only cross-sectional associative analyses are available in CD 
patients. In addition, the present study provides longitudinal prospective results on the 
predictive potential of PAbsfor identifying disease specific complications and surgery 
requirements.PAb positivity was able to predict faster progression to complicated 












surgical interventions.while anti-CUZD1 predicted development of perianal 
complications.Regarding anti-GP2, previously only two cross-sectional studies 
evaluated surgical outcome with conflicting results16, 18Of note however, treatment 
strategy may vary among countries, IBD centres and even doctors which is a clear 
confounder of all studies. Thereforeassociation between serology and surgical 
findings in the present study should be interpreted with caution.. However, one of the 
main strengths of our study is the analysis of outcomes during a prospective follow-up 
period. The frequency of regular follow-up was 3-6 months in the majority of the 
patients. Silverberg et al.20 suggested that long-term complications and outcomes 
should be studied during an approximate 5-year follow-up. Of note, 79.2% of the CD 
patients in the present cohort had at least a 5-year follow-up. In addition, the 
collection of extensive disease phenotypes enabled adjusting for possible 
confounders. In the final Cox-regression multivariate model, anti-CUZD1 antibody 
positivity was a strong independent predictor for the development of perianal 
complicationsincluding age at diagnosis, sex, disease location and behavior and 
relapse frequencyas potential confounders.Our results await replication in 
independent patient cohorts both from referral centers and population-based cohorts. 
Interestingly, in our study IgA,but not IgG PAbs typeswere associated with 
complicated diseases course in CD.The gut mucosal immune system plays a central 
role in the IgA antibody formation and this may at least partly reflect an immune 
response against an overwhelmed microbial challenge.In addition, IgA type 
autoantibodies are considered a sign of immunological response to enteric antigens in 
other diseases associated with enhanced bacterial translocation.Moreover IgA type 
antibodies were reported to have a pivotal role in the development of disease-specific 












concordance with a previous hypothesis fromRoggenbuck et al.12, 17.According to this 
hypothesis, plasma cells can synthesize anti-GP2 IgA after the loss of tolerance 
towards GP2, which will be actively transported by the epithelium into the intestinal 
lumen. Indeed, anti-GP2 IgA has been found in faeces of patients with pouchitis 
exhibiting CD-like complications38. The secreted anti-GP2 IgA can bridge FimH 
positive bacteria opsonised by pancreatic GP2 with the membrane-bound GP2 on the 
M cells. Ultimately, this may lead to a mucosal overload of microbes in CD due to 
elevated transcytosis accelerating intestinal inflammation. 
 In conclusions, the findings of our prospective referral cohort study indicate 
that target-specific PAbsmay be useful markers in the stratification of CD patients and 
are associated with complicated disease phenotype and risk of developing perianal 
complications. In addition, they may be valuable additional tools as a member of 
serology panels for the prediction of disease course.  
 
FUNDING:This work was supported bythe Janos Bolyai Research Scholarship of the 
Hungarian Academy of Sciences, Internal Research Grant of University of Debrecen 
and IOIBD Research Grant. 
 
CONFLICT OF INTEREST: None. 
 
ACKNOWLEDGEMENTS:  
Author contributions: (1) Papp M, Lakatos PL, Antal-Szalmas P, Veres G, Altorjay 
I made the concept and designed the present study. Sipeki N, Tornai T, Papp M made 
the acquisition of data. Papp M, Lakatos PL, Sipeki N, Norman GL, Zakera S, 
Roggenbuck D, Fechner K, Stöcker W made the analysis and interpretation of the 












Altorjay I, Tornai T, Norman GL, Zakera S, Roggenbuck D, Fechner K, Stöcker W 
revised the article critically for important intellectual content. (3) All authors 















1. Laass MW, Roggenbuck D, Conrad K. Diagnosis and classification of Crohn's 
disease. Autoimmunity reviews 2014;13:467-471. 
2. Papp M, Lakatos PL. Serological studies in inflammatory bowel disease: how 
important are they? Curr Opin Gastroenterol 2014;30:359-364. 
3. Roggenbuck D, Reinhold D, Schierack P, Bogdanos DP, Conrad K, Laass 
MW. Crohn's disease specific pancreatic antibodies: clinical and 
pathophysiological challenges. Clinical chemistry and laboratory medicine : 
CCLM / FESCC 2014;52:483-494. 
4. Stocker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stocker K, Jantschek 
G, Scriba PC. Autoimmunity to pancreatic juice in Crohn's disease. Results of 
an autoantibody screening in patients with chronic inflammatory bowel 
disease. Scand J Gastroenterol Suppl 1987;139:41-52. 
5. Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, 
Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller 
P, Barta Z, Stocker W, Papp J, Veres G, Papp M, Hungarian IBDSG. 
Pancreatic autoantibodies are associated with reactivity to microbial 
antibodies, penetrating disease behavior, perianal disease, and extraintestinal 
manifestations, but not with NOD2/CARD15 or TLR4 genotype in a 
Hungarian IBD cohort. Inflamm Bowel Dis 2009;15:365-374. 
6. Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes 
A, Laass MW, Conrad K. Diagnostic value, clinical utility and pathogenic 
significance of reactivity to the molecular targets of Crohn's disease specific-












7. Conrad K HG, Feist E, Reinhold D, Jungblut P, Porstmann T, et al. . 
Identification of GP2 as the major autoantigen of pancreatic autoantibodies. 
Porto; Portugal, 2008:A1356. 
8. Stöcker W GM, Probst C, Teegen B, Friedrich A, Sokolowski S, et al. 
Identification of two different proeoglycans from exocrine pancreas as the 
long sought after autoantigens in Crohn's disease: CUZD1 and GP2. Porto; 
Portugal:A1177. 
9. Komorowski L, Teegen B, Probst C, Aulinger-Stocker K, Sina C, Fellermann 
K, Stocker W. Autoantibodies against exocrine pancreas in Crohn's disease are 
directed against two antigens: the glycoproteins CUZD1 and GP2. J Crohns 
Colitis 2013;7:780-790. 
10. Ohno H, Hase K. Glycoprotein 2 (GP2): grabbing the FimH bacteria into M 
cells for mucosal immunity. Gut microbes 2010;1:407-410. 
11. Schierack P, Rodiger S, Kolenda R, Hiemann R, Berger E, Grzymajlo K, 
Swidsinski A, Juretzek T, Meissner D, Mydlak K, Reinhold D, Nolan LK, 
Roggenbuck D. Species-specific and pathotype-specific binding of bacteria to 
zymogen granule membrane glycoprotein 2 (GP2). Gut 2015;64:517-519. 
12. Roggenbuck D, Reinhold D, Werner L, Schierack P, Bogdanos DP, Conrad K. 
Glycoprotein 2 antibodies in Crohn's disease. Advances in clinical chemistry 
2013;60:187-208. 
13. Roggenbuck D, Reinhold D, Wex T, Goihl A, von Arnim U, Malfertheiner P, 
Buttner T, Porstmann T, Porstmann S, Liedvogel B, Bogdanos DP, Laass 
MW, Conrad K. Autoantibodies to GP2, the major zymogen granule 













14. Pavlidis P, Shums Z, Koutsoumpas AL, Milo J, Papp M, Umemura T, Lakatos 
PL, Smyk DS, Bogdanos DP, Forbes A, Norman GL. Diagnostic and clinical 
significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by 
a novel ELISA. Clin Chim Acta 2015;441:176-181. 
15. Bogdanos DP, Roggenbuck D, Reinhold D, Wex T, Pavlidis P, von Arnim U, 
Malfertheiner P, Forbes A, Conrad K, Laass MW. Pancreatic-specific 
autoantibodies to glycoprotein 2 mirror disease location and behaviour in 
younger patients with Crohn's disease. BMC Gastroenterol 2012;12:102. 
16. Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, 
Liaskos C, Smyk DS, Koutsoumpas AL, Rigopoulou EI, Conrad K, Forbes A, 
Bogdanos DP. Ileal inflammation may trigger the development of GP2-
specific pancreatic autoantibodies in patients with Crohn's disease. Clinical & 
developmental immunology 2012;2012:640835. 
17. Somma V, Ababneh H, Ababneh A, Gatti S, Romagnoli V, Bendia E, Conrad 
K, Bogdanos DP, Roggenbuck D, Ciarrocchi G. The Novel Crohn's Disease 
Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of 
Disease. Gastroenterology research and practice 2013;2013:683824. 
18. Op De Beeck K, Vermeire S, Rutgeerts P, Bossuyt X. Antibodies to GP2, the 
major zymogen granule membrane glycoprotein, in inflammatory bowel 
diseases. Gut 2012;61:162-164; author reply 164-165. 
19. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J 
Gastroenterol Suppl 1989;170:2-6; discussion 16-19. 
20. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, 
Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus 












SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and 
serological classification of inflammatory bowel disease: report of a Working 
Party of the 2005 Montreal World Congress of Gastroenterology. Can J 
Gastroenterol 2005;19 Suppl A:5A-36A. 
21. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, 
Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C, Tilg H, 
Schreiber SW, Scholmerich J, Reinisch W, European Cs, Colitis O. European 
evidence based consensus on the diagnosis and management of Crohn's 
disease: definitions and diagnosis. Gut 2006;55 Suppl 1:i1-15. 
22. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation 
between the Crohn's disease activity and Harvey-Bradshaw indices in 
assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010;8:357-
363. 
23. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use 
of the noninvasive components of the Mayo score to assess clinical response 
in ulcerative colitis. Inflamm Bowel Dis 2008;14:1660-1666. 
24. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, 
Ochsenkuhn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, 
Travis S, Stange E, European Cs, Colitis O. The second European evidence-
based Consensus on the diagnosis and management of Crohn's disease: 
Definitions and diagnosis. J Crohns Colitis 2010;4:7-27. 
25. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, 
Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. 
Development and validation of a new, simplified endoscopic activity score for 












26. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid 
therapy for mildly to moderately active ulcerative colitis. A randomized study. 
N Engl J Med 1987;317:1625-1629. 
27. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, 
Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, 
Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, 
Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell 
R, Hawkey CJ. European evidence based consensus on the diagnosis and 
management of Crohn's disease: special situations. Gut 2006;55 Suppl 1:i36-
58. 
28. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel 
JF, Danese S, D'Hoore A, Gassull M, Gomollon F, Hommes DW, Michetti P, 
O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP. The second 
European evidence-based Consensus on the diagnosis and management of 
Crohn's disease: Current management. J Crohns Colitis 2010;4:28-62. 
29. Esser D, Cornillie F, Diamond RH, Spiegel RJ. On the updated ECCO 
consensus guidelines for medical management of Crohn's disease. J Crohns 
Colitis 2011;5:165-166. 
30. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D'Haens 
G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, 
Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ. European 
evidence based consensus on the diagnosis and management of Crohn's 
disease: current management. Gut 2006;55 Suppl 1:i16-35. 
31. Papp M, Lakatos PL, Harsfalvi J, Farkas G, Palatka K, Udvardy M, Molnar T, 












J, Hungarian IBDSG, Altorjay I. Mannose-binding lectin level and deficiency 
is not associated with inflammatory bowel diseases, disease phenotype, 
serology profile, and NOD2/CARD15 genotype in a large Hungarian cohort. 
Hum Immunol 2010;71:407-413. 
32. Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Buttner T, 
Jungblut PR, Porstmann T, Laass MW, Henker J, Buning C, Feist E, Conrad 
K. Identification of GP2, the major zymogen granule membrane glycoprotein, 
as the autoantigen of pancreatic antibodies in Crohn's disease. Gut 
2009;58:1620-1628. 
33. Gross S, Bakker SF, van Bodegraven AA, van Hoogstraten IM, Gelderman 
KA, Bouma G, Mulder CJ, von Blomberg BM, Bontkes HJ. Increased IgA 
glycoprotein-2 specific antibody titres in refractory celiac disease. Journal of 
gastrointestinal and liver diseases : JGLD 2014;23:127-133. 
34. Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, Genin C, Sparrow M, 
Roblin X, Paul S. Systematic review: new serological markers (anti-glycan, 
anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. 
Autoimmunity reviews 2015;14:231-245. 
35. Roggenbuck D, Rober N, Bogdanos DP, Goihl A, Reinhold D, Conrad K, 
Laass MW. Autoreactivity to isoforms of glycoprotein 2 in inflammatory 
bowel disease. Clin Chim Acta 2015;442:82-83. 
36. Fukuoka S. Molecular cloning and sequences of cDNAs encoding alpha 
(large) and beta (small) isoforms of human pancreatic zymogen granule 
membrane-associated protein GP2. Biochim Biophys Acta 2000;1491:376-380. 
37. Papp M, Sipeki N, Vitalis Z, Tornai T, Altorjay I, Tornai I, Udvardy M, 












Kappelmayer J, Antal-Szalmas P. High prevalence of IgA class anti-neutrophil 
cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial 
infection in patients with cirrhosis. J Hepatol 2013;59:457-466. 
38. Werner L, Sturm A, Roggenbuck D, Yahav L, Zion T, Meirowithz E, Ofer A, 
Guzner-Gur H, Tulchinsky H, Dotan I. Antibodies against glycoprotein 2 are 
novel markers of intestinal inflammation in patients with an ileal pouch. J 















Figure 1 Flow chart of the patients with Crohn’s disease (CD) in the cohort 
study. Event: complication and/or surgery; Complication: stricture development 
and/or internal penetration and/or perianal penetration; Surgery: CD-related surgery 
(resection only). Pts: patients 
 
Figure 2 Kaplan-Meier survival analysis for the probability of the perianal 
disease development  
 
















Table 1 Clinical characteristics of IBD patients  
 
Table 2 Serologic markers in patients with Crohn’s disease (CD), ulcerative 
colitis (UC), and healthy controls (HCONT). 
 
Table 3 Associations between antibody reactivities to different PAbs and diseases 
characteristics in patients with Crohn’s disease at diagnosis (A) and last follow 
up (B). Positive associations are indicated in bold and negative associations in italic 
(p values, odds ratio and 95%CI). 
 
Table 4 Summary of Cox Proportional Hazard Regression Model: factors 
affecting time to development of perianal disease (A) and need for resective 





















Male/female (n) 115/156 86/101 
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                            L2 
                            L3 
                            L4 only 











left-sided  104 (55.6%) 
extensive     53 (28.3%) 
Behavior at diagnosis
1 
                            B1 
                            B2 

















Cumulative exposure of medication and surgeries during follow-up 
Steroid use/refractory
1 239 (88.2%) / 
31 (13.0%) 
144 (77.0%)/ 
 11 (7.6%) 
Azathioprine use
1 200 (73.8%) 66 (35.3%) 
























☐: 265 CD patients had follow-up 
1n (%), *: median (IQR) 
Location: L1: ileal, L2: colonic, L3: ileocolonic, L4: upper gastrointestinal disease 
Behavior: B1: non-stricturing/ non-penetrating, B2: stenosing, B3: penetrating 














Table 2. Serologic markers in patients with Crohn’s disease (CD), ulcerative 

















































































































































Cut-off levels were 25 U/ml for anti-GP2, 20 U/ml for anti-MZGP2 by enzyme-linked 
immunosorbent assay and 1:10 titer for anti-rPAg antibodies by indirect 
immunofluorescence assay. 
Anti-rPAgA1 and rPAgA2 corresponds to anti-CUZD1 and anti-GP2, respectively. 
 
CD vs. controls: §p=0.015, *p=0.01, **p=<0.01, p= 0.001,⌘p<0.001,  
























Table 3. Associations between antibody reactivities to different PAbs and diseases characteristics or other serologic markers in patients 
with Crohn’s disease at diagnosis (A) and last follow-up (B). Rows corresponding to location and perianal disease at diagnosis, 
NOD2/CARD15 mutations and need for systemic GCS at last follow-up were omitted because statistically significant differences for a given 
parameter were not obtained; positive associations are indicated in bold and negative associations in italic (p values, odds ratio and 95%CI). 




 Anti-GP2 Anti-MZGP2 Anti-rPAg2 (≈anti-GP2) Anti-rPAg1 (≈anti-CUZD1) 
 IgA IgG IgA and/ 
or IgG 
IgA IgG IgA and/ 
or IgG 
IgA IgG IgA and/ 
or IgG 
IgA IgG IgA and/ 
or IgG 
Pediatric onset 









      
Colon 
involvement 


















  <0.001 
10.17 
(2.32–44.5) 










   0.003 
4.68 
(1.67–13.13) 















 Anti-GP2 Anti-MZGP2 Anti-rPAg2 (≈anti-GP2) Anti-rPAg1 (≈anti-CUZD1) 
 IgA IgG IgA and/ 
or IgG 
IgA IgG IgA and/ 
or IgG 
IgA IgG IgA and/ 
or IgG 
IgA IgG IgA and/ 
or IgG 
Perianal disease 





























     











         
Cutaneous 
Manifestation 


























Table 4 Summary of Cox Proportional Hazard Regression Model: factors 
affecting time to development of perianal disease (A) and need for resective 
surgery (B) in patients with Crohn’s disease. Positive associations are indicated in 
bold 
p value: level of significance; 95% CI: 95% confidence interval, NSNP: non-
stricturing non-penetrating 
A 
 p value Hazard Ratio 95% CI 
Female gender 0.275 0.70 0.36-1.33 
Age at onset 0.13 
> 40 yrs Reference 
17-40 yrs 0.088 5.84 0.77-44.36 
≤ 16 yrs 0.049 8.42 1.01-70.39 
Frequent relapse < 0.001 3.50 1.78-6.89 
Colon 
involvement 
0.044 4.41 1.04-18.73 
Behaviour 0.267 
NSNP Reference 
Stricturing 0.368 1.58 0.58-4.30 
Penetrating 0.137 2.65 0.73-9.59 
Anti-CUZD1 IgA 
positivity 





 p value Hazard Ratio 95% CI 
Female gender 0.970 0.99 0.66-1.49 
Age at onset 0.813 
> 40 yrs Reference 
17-40 yrs 0.540 0.84 0.47-1.48 
≤ 16 yrs 0.821 0.91 0.40-2.05 
Ileal involvement 0.129 1.44 0.90-2.32 
Behaviour < 0.001 
NSNP Reference 
Stricturing < 0.001 5.45 3.27-9.10 
Penetrating < 0.001 12.48 6.69-23.28 
Anti-GP2 IgA 
positivity 


























Figure 2 Kaplan-Meier survival analysis for the probability of the resective surgery  




















Figure 3 Kaplan-Meier survival analysis for the probability of the perianal disease development  
 
 
